92243-56-6

Upstream product

• 26505-64-6 trans-3-phenylcyclobutanol tosylate 
• 26505-63-5 cis-3-phenylcyclobutanol tosylate 
• 52784-31-3 3-Phenylcyclobutanone 
• 13866-28-9 2,2-dichloro-3-phenylcyclobutanone 
• 100-42-5 styrene 
• 21213-27-4 phenyl 1-phenyl-3-butenyl sulfide 
• 917-64-6 methyl magnesium iodide 
• 67100-15-6 2-(2-phenyl-2-(phenylsulfonyl)ethyl)oxirane 

Downstream Products

• 150639-16-0 (1r,3r)-3-phenylcyclobutanol 
• 150639-15-9 (1s,3s)-3-phenylcyclobutanol 
• 1227622-83-4 C₂₄H₂₈ClNO₄ 
• 38425-47-7 3-phenyl-2-cyclobuten-1-one 
• 16251-77-7 3-Phenylbutyraldehyde 

Relevant academic research and scientific papers

Synthesis of 1-Pyrroline by Denitrogenative Ring Expansion of Cyclobutyl Azides under Thermal Conditions

We herein report an efficient and systematic synthesis of 1-pyrrolines from cyclobutyl azides under thermal and neutral conditions. The reaction proceeded without any additional reagents, and nitrogen was generated as the sole by-product. Furthermore, the generated 1-pyrrolines could be continuously transformed into pyrroles, N-Boc-amines, and oxaziridines in an one-pot manner. (Figure presented.).

COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR

The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.

Baeyer–Villiger monooxygenase-catalyzed desymmetrizations of cyclobutanones. Application to the synthesis of valuable spirolactones

A series of γ-butyrolactone derivatives, including some spiranic ones, was obtained through desymmetrization of the corresponding prochiral 3-substituted cyclobutanones via Baeyer–Villiger monooxygenase (BVMO)-catalyzed oxidation. After reaction optimization using several commercial enzymes, both antipodes of various lactones were synthesized in most cases with >90% conversion and >80% enantiomeric excess under mild reaction conditions. In some cases alcohol formation was also observed (up to 40% conversion) as an undesired side reaction due to the presence of alcohol dehydrogenases in these preparations. Selected transformations were achieved on a 100 mg scale showing the possibilities of these oxidative biocatalysts as a new source of highly interesting compounds.

Rh(II)-catalyzed [2,3]-sigmatropic rearrangement of sulfur ylides derived from N-tosylhydrazones and sulfides

In this paper, Rh2(OAc)4-catalyzed [2,3]-sigmatropic rearrangement of sulfur ylides derived from N-tosylhydrazones and sulfides is reported. A series of tosylhydrazones derived from aldehydes were successfully used for [2,3]-sigmatropic rearrangement by reaction with either allylic phenyl sulfides or propargyl phenyl sulfides. The reaction conditions were optimized and afforded the products in moderate to good yields. In addition, a novel and convenient approach for the synthesis of cyclobutenones and cyclopropanes has been developed through direct oxidation of the rearrangement products.

SEROTONIN RECEPTOR MODULATORS

The biphenyic compounds of formula (I) are serotonin modulators useful in the treatment of serotonin-mediated diseases.

Products from solvolysis reactions that form (2-phenylcyclopropyl)carbinyl cations

Products from solvolytic reactions that form the (2-phenylcyclopropyl) carbinyl cation were determined. The majority of products (> 98%) derived from the 1-phenyl-3-butenyl cation, consistent with reports by Wiberg and co-workers. Small amounts of products derived from the 1-phenyl-1- cyclopropylmethyl cation also were found; these products were previously predicted to be formed from reactions of the title cation. Although the 1-phenyl-1-cyclopropylmethyl cation is considerably more stable than the 1-phenyl-3-butenyl cation, it is not kinetically accessible under a variety of solvolytic conditions. Copyright

EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS

The invention features a method of treating rheumatoid arthritis in a mammal comprising administering an agent that inhibits prostaglandin EP4 receptor (EP4) activity. Also featured is a method of identifying agents that selectively inhibit EP4 activity in vivo.